Bisphosphonates are a class of drugs that slow bone loss by inhibiting osteoclasts, the cells responsible for bone resorption. Their primary healthspan relevance is the prevention of osteoporosis and associated fractures, which are a major cause of morbidity, loss of independence, and mortality in older adults. Some observational data suggests a potential reduction in all-cause mortality, though the mechanism is not fully understood.
Verdict
Highly effective for bone health, a crucial component of healthspan.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$10 - $150
Protocol
- Oral forms are typically taken daily, weekly, or monthly (e.g., alendronate 70mg once weekly).
- Intravenous forms are administered less frequently, such as quarterly or yearly (e.g., zoledronic acid 5mg once yearly).
Flags
- Requires a prescription and medical supervision.
- Oral forms can cause significant gastrointestinal and esophageal irritation.
- Long-term use is associated with rare risks of osteonecrosis of the jaw (ONJ) and atypical femur fractures.
- Proper administration of oral pills (e.g., with water, remaining upright) is critical to minimize side effects.
- Contraindicated in patients with severe kidney impairment.
- Absorption is significantly reduced by food, calcium, and antacids.